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Objective: Various types of natural and synthetic scaffolds with arterial tissue cells or
differentiated stem cells have recently attracted interest as potential small-caliber vas-
cular grafts. It was thought that the synthetic graft with the potential to promote autol-
ogous tissue regeneration without any seeding would be more practical than a seeded
graft. In this study, we investigated in situ tissue regeneration in small-diameter
arteries using a novel tissue-engineered biodegradable vascular graft that did not
require ex vivo cell seeding.
Methods: Small-caliber vascular grafts (4 mm in diameter) were fabricated by com-
pounding a collagen microsponge with a biodegradable woven polymer tube that
was constructed in a plain weave pattern with a double layer of polyglycolic acid
(core) and poly-L-lactic acid (sheath) fibers. We implanted these tissue-engineered
vascular grafts bilaterally into the carotid arteries of mongrel dogs (body weight,
20–25 kg). No anticoagulation regimen was used after implantation. We sacrificed
the dogs 2, 4, 6, and 12 months (n5 4 in each group) after implantation and evaluated
the explants histologically and biochemically.
Results: All of the tissue-engineered vascular grafts were patent with no signs of
thrombosis or aneurysm at any time. Histologic and biochemical examinations
showed excellent in situ tissue regeneration with an endothelial cell monolayer,
smooth muscle cells, and a reconstructed vessel wall with elastin and collagen fibers.
Conclusion: Our study indicated that this novel tissue-engineered vascular graft
promoted in situ tissue regeneration and did not require ex vivo cell seeding, thereby
conferring better patency on small-caliber vascular prostheses.
I
n the area of vascular surgery, vascular prostheses prepared from expanded poly-
tetrafluoroethylene (ePTFE) or Dacron are clinically used for reconstructing
large-diameter arteries, such as the aorta and iliac artery. However, these synthetic
materials are clinically unacceptable for reconstructing small-diameter arteries (ie, in-
ner diameter of, 5 mm), which are required in lower-extremity bypass and coronary
artery bypass grafting procedures, because they are foreign bodies and thrombosis can
occur on the luminal surface, resulting in occlusion. For such small artery bypass
grafting procedures, autologous arterial (eg, internal thoracic artery and radial artery)
or venous (eg, saphenous vein) grafts still remain the most ideal vascular substitutes.
However, they cannot always be used because of their poor quality and inadequate
size or length. Moreover, a second surgical procedure is required to obtain the vessel.
Thus, it is imperative to develop innovative technologies targeting the fabrication of
small-caliber vascular grafts.
The concept of tissue engineering using biodegradable materials was recently pro-
posed,1 and suchmaterials have been developed and clinically appliedwith autologous
cell seeding or bioreactor culturing.2-9 However, the usefulness of these materials for
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reconstruction of small-caliber vascular grafts has not been
demonstrated. Moreover, pretreatment with autologous cell
seeding or bioreactor culturing can be complicated and inva-
sive, and will render the graft prone to infection. We previ-
ously developed a tissue-engineered patch prepared from
biodegradable polymer with collagen microsponge that did
not require pretreatment and showed good in situ tissue re-
generation of the autologous vessel tissue in both venous
and arterial grafts.10
In the present study, we developed a novel tissue-
engineered small-caliber vascular graft that did not require
pretreatment with cell seeding and promoted autologous
tissue regeneration by inducing the proliferation and differen-
tiation of endothelial and smooth muscle progenitor cells
after implantation. The objective of this study was to investi-
gate the biological performance and biochemical characteris-
tics of this graft.
Materials and Methods
Scaffold Design
A newly designed small-caliber vascular graft (4 mm in diameter)
was fabricated by compounding a collagen microsponge with a cy-
lindrically woven biodegradable and absorbable polymer tube that
was constructed using core-sheath compound yarn with polygly-
colic acid (PGA) and poly-L-lactic acid (PLLA) fibers (Figure 1,
A and B). The core-sheath yarn was fabricated by air-jet spinning
technology using a core thread composed of 30 PLLA fibers
(each having a diameter of 20 mm) and a sheath thread composed
of 56 PGA fibers (each having a diameter of 15 mm). The core-
sheath yarn thus created had a porous 3-dimensional structure. All
of these materials are biocompatible and biodegradable, and have
received Food and Drug Administration clearance. These tissue-
engineered vascular grafts (TEVGs) were provided by Senko Med-
ical Instrument Manufacturing Co Ltd (Tokyo, Japan). In addition,
TEVGs with the collagen microsponge were prepared using bovine
type I collagen. The techniques for fabricating the collagen micro-
sponge are described in detail by Chen.11 Briefly, the PGA/PLLA
tube graft was immersed in a solution containing type I collagen
(Koken Co Ltd, Tokyo, Japan), frozen at –80C for 12 hours, and
lyophilized in a vacuum of 0.2 mm Hg for an additional 24 hours
to allow the formation of the collagen microsponge. The collagen
microsponge was further cross-linked by treatment with glutaralde-
hyde vapor through exposure to a 25% glutaraldehyde aqueous so-
lution at 37C for 4 hours. The graft structure and collagen
microsponge are thought to have good cell attachment properties,
and they promote in situ tissue regeneration because of their porous
3-dimensional structures. The scanning electron micrographs of theThe Journal of Thdouble-layered thread structure and graft surface are shown in Fig-
ure 1, C, D, and E.
In Vitro Study of Cell Culture Growth
To verify the cellular affinity and proliferative ability of the collagen
microsponge, murine fibroblasts (NIH3T3; American Type Culture
Collection, Manassas, Va) and human umbilical vascular endothe-
lial cells (Cambrex, East Rutheford, NJ) were seeded at a cell den-
sity of 300 cells/mm2 onto the 2 sets of TEVGs with the collagen
microsponge (n 5 6) or without it (n 5 6). After culture for 3
days in the routine manner, the surfaces of TEVGs were observed
by scanning electron microscopy, and the number of cells attached
to the graft was counted by a water-soluble tetrazolium assay (Cell
Counting Kit; Dojindo Chemicals, Japan).
In Vivo Study of Implantation in Mongrel Dogs
We used 24 mongrel dogs (weight, 20–25 kg) in this study. All an-
imals were anesthetized by intramuscular injection of 10 mg/kg ket-
amine (Sankyo Co, Tokyo, Japan) and 2 mg/kg of xylazine (Bayer
Medical Co, Tokyo, Japan) followed by intubation and mechanical
ventilation. An adequate level of anesthesia was maintained by
intravenous continuous infusion of propofol (AstraZeneca, Osaka,
Japan) at a rate of 4 mg/kg/h throughout the operative procedure
and additional injections of ketamine (5 mg/kg/h). Bilateral carotid
artery grafting was performed using TEVGs (4 mm in diameter, 30
mm in length). The bilateral carotid arteries were carefully exposed
through a midline neck incision, and 100 IU/kg of heparin was ad-
ministered intravenously before vascular clamping. The grafts were
interposed in the carotid arteries, and proximal and distal end-to-end
anastomoses were performed with continuous sutures of 7-0 mono-
filament polypropylene. All surgeries were successful, and there was
no significant bleeding from the vascular graft after declamping the
carotid arteries. Finally, protamine was administered intravenously,
and the neck incision was closed. Antibiotics were given intrave-
nously during surgery, but anticoagulants or antiplatelets were not
administered postoperatively. After the surgical procedure was com-
pleted, the animal was extubated and resumed normal activities. At
2, 4, 6, and 12 months after implantation (n5 4 in each group), the
animals were anesthetized again by the same method as above. The
neck incision was reopened, the surgical site was examined for ad-
hesions and fibrosis, and the implanted graft was carefully exposed.
The animal was euthanized, and the grafts were carefully explanted
and processed immediately or frozen for morphologic, histologic,
immunohistochemical, and biochemical examinations. As the con-
trol, 8 ePTFE grafts of the same size were implanted in the same
manner and explanted 2, 4, 6, and 12 months after implantation (n
5 2 in each group). The investigation conforms to the Principles
of Laboratory Animal Care, formulated by the National Society
for Medical Research, and the Guide for the Care and Use of Lab-
oratory Animals, published by the National Academy of Science
and the National Institutes of Health (Publication No. 86–23, revised
1996).
Morphologic Examination
The explanted grafts were incised longitudinally and flattened with
their luminal side facing upward. The lumina were photographed in
detail after gross examination. The middle portions of specimens
were prepared in a typical fashion for scanning electron microscopyoracic and Cardiovascular Surgery c Volume 136, Number 4 901
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S-800; Hitachi, Tokyo, Japan).
Histologic and Immunohistologic Examination
Longitudinal samples of the explanted grafts were fixed in 10%
buffered formalin and embedded in paraffin. Each cross-section
that included the native tissue proximal and distal to TEVGs was ex-
amined by double staining with hematoxylin-eosin and Victoria
blue, and with elastica van Gieson stain. Immunohistologic staining
was also performed to identify the cell types in the explanted tissue
specimens of the vascular grafts. The antibodies for immunohisto-
chemistry included monoclonal antibody to a-smooth muscle actin
(clone 1A4; DAKO, Carpenteria, Calif), and polyclonal antibody to
von Willebrand factor (Cat N: N1505, DAKO).
Biochemical Examination
Collagen formation in the explanted grafts was quantified to evaluate
thedegreeof regenerationof the autologous tissue.Thehydroxyproline
content of the lyophilized sampleswasdetermined as an indicator of the
collagen content using a modification of the assay described by Huzer
Figure 1. The newly designed small-
diameter vascular graft (A, B) was fabri-
cated using a biodegradable woven
polymer tube constructed in a plain
weave pattern using a double-layered
thread with PLLA fibers as the core and
PGA fibers as the sheath. Scanning elec-
tron micrograph of the double-layered
thread (C). The graft surface shows
the porous 3-dimensional structure (D)
and interconnected pore structure after
incorporation of the collagen micro-
sponge (E) (magnification, 1003).
Figure 2. The number of cells of NIH3T3
(A) and human umbilical vascular
endothelial cells (B) cultured for 3 days
in vitro on TEVGs with/without the col-
lagen microsponge. Scanning electron
micrographs of the same samples with
NIH3T3 (C) and human umbilical vascu-
lar endothelial cells (D) cultured for
3 days in vitro. HUVEC, Human umbilical
vascular endothelial cell.902 The Journal of Thoracic and Cardiovascular Surgery c October 2008
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CDFigure 3. Macroscopic appearance of TEVGs 2
(A), 4 (B), 6 (C), and 12 (D) months after implanta-
tion and of the ePTFE graft 12 months after implan-
tation (E). The scale bar represents 10 mm.and colleagues12 and a standard curve from trans-4-hydroxyproline
(Sigma, St Louis, Mo). The measured amounts of hydroxyproline in
the samples were compared with those in the native carotid arteries
(n5 16).
Biomechanical Examination
Themechanical properties of TEVGs and native carotid arteries were
evaluated using a tensile testingmachine (Tensilon;Orientec, Tokyo,
Japan). Longitudinal strips measuring 203 5 mm each were placed
within the clamps of the tensile tester and pulled circumferentially to
failure at a rate of 10 mm/min. The tensile force and displacement
were recorded, and the tensile strength and modulus were calculated.
Statistical Analysis
The results of quantitative studieswere expressed as themean6 stan-
dard deviation and analyzedusing a statistical analysis software pack-
age (Stat-View version 5.0; Abacus Concepts Inc, Berkeley, Calif).
A standard t test was used to determine the significance of the
difference between the 2 means, and the appropriate analysis of var-
iance and Tukey-Kramer’s post hoc test were used to compare the
measured data among multiple groups. P values of less than .05
were considered to be statistically significant.
Results
In Vitro Study of Cell Culture Growth
Three days after implantation (experimental day 3), scanning
electron microscopy images showed that NIH3T3 and humanThe Journal of Thorumbilical vascular endothelial cells were more closely adher-
ent to andmore expanded in TEVGswith the collagen sponge
than in those without the collagen sponge (Figure 2,C andD).
The cell count test with both cell lines indicated that the num-
ber of proliferated cells attached to TEVGs with the collagen
microsponge was significantly large, compared with TEVGs
without the collagen microsponge (Figure 2, A and B).
In Vivo Study of Implantation in Mongrel Dogs
All surgeries were completed successfully, and all animals
remained in good health. No dogs presented with signs of lo-
cal or systemic infection during the entire observation period
until they were sacrificed.
Morphologic Examination
At the time of graft explantation, there was no unusual adhe-
sion, perigraft hematoma, perigraft seroma, or inflammatory
reaction. There was no gross evidence of stenosis, aneurysm,
or suture dehiscence at any point of time. The luminal sur-
faces of all 32 explanted TEVGs were smooth and shiny
with no evidence of thrombosis (Figure 3, A–D). The anasto-
motic sites were smooth and not stenosed. Macroscopically,
the surfaces were completely endothelialized. In ePTFE
grafts, however, the luminal surfaces were not completely
endothelialized at any time (Figure 3, E), and 2 grafts were
occluded 12 months after implantation. Scanning electronacic and Cardiovascular Surgery c Volume 136, Number 4 903
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CDFigure 4. Scanning electron micro-
graph of the luminal surfaces of TEVGs
2 (A), 4 (B), 6 (C), and 12 (D) months after
implantation, compared with that of the
ePTFE graft 12 months after implanta-
tion (E) (magnification, 5003).microscopy showed that the luminal surfaces of TEVGs were
overlaid with confluent endothelial cells oriented parallel to
the direction of the blood flow (Figure 4), and a cross-section
of TEVGs showed that PGA fibers were completely absorbed
as early as 2 months after implantation; however, PLLA
fibers remained unabsorbed throughout the entire study
(data not shown).
Histologic and Immunohistologic Examinations
The explanted TEVGshad a 3-layered structure at all points of
time, which was reminiscent of the natural arterial structure
(Figure 5). The luminal surface of the newly formed tissue
(particularly the intima) showed a complete endothelializa-
tion with a confluent endothelial layer consisting of von Wil-
lebrand factor-positive cells. The central layer (essentially,
the media) was composed of parallel-aligned a-smooth mus-
cle actin positive smooth muscle cells and residual scaffold
material. The extracellular matrix (ECM) was stained by Vic-
toria blue and elastica van Gieson. The intensity of staining of
multilayered elastin and collagen increasedwith time, indicat-
ing the biosynthesis of elastic and collagen fibers. The outer
surface (essentially, the adventitia) was composed of the loose904 The Journal of Thoracic and Cardiovascular Surgery c Occonnective tissue. The neointimal and medial wall thickness
progressively condensed with time, peaked 6 months after
implantation, and tissue regeneration slowed down subse-
quently. Furthermore, no significant differences were ob-
served in the neointimal or medial wall thickness among the
proximal, middle, and distal portions of the graft (Figure 6).
Biochemical Examination
The 4-hydroxyproline assay showed that the amount of colla-
gen in theneotissueofTEVGs increasedwith time. Sixmonths
after implantation, the collagen content in TEVGs was almost
the same as that in the native vascular tissue (Figure 7).
Biomechanical Characterization
After implantation, the strength of TEVGs and neotissue
decreased, and the pliability increased to be almost equivalent
to that of the native carotid artery. The mechanical tensile
strength of TEVGs and neotissue decreased by one half of the
preimplantation values (n5 8) and reached a level that was al-
most equivalent to that of thenative carotid artery.After implan-
tation, the tensilemodulus of them also reached a level that was
almost equivalent to that of the native carotid artery (Figure 8).tober 2008
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CDFigure 5. Double staining with hematoxylin-eosin and Victoria blue stain (A), immunohistochemical double staining
with vonWillebrand factor and a-smooth muscle actin (B), and elastica van Gieson (C) of the PGA/PLLA tube graft 2,
4, 6, and 12 months after implantation, and those of the ePTFE graft 12 months after implantation. The scale bar rep-
resents 100 mm. H&E, Hematoxylin-eosin; vWF, von Willebrand factor; SMA, smooth muscle actin; EVG, elastica van
Gieson; ePTFE, expanded polytetrafluoroethylene.Discussion
There is a need to develop novel vascular grafts that function
well in small-diameter applications because small-caliber vas-
cular grafts are associated with high rates of graft failure. One
innovation designed to improve the patency of such grafts is
the creation of living autologous replacement materials by
methods of tissue engineering. The ultimate goal of tissue
engineering is to construct the tissues with characteristics of
healthy native tissues from their cellular components. Various
types of natural and synthetic scaffolds with arterial tissue
cells or differentiated stem cells have attracted much interest
as potential small-caliber vascular grafts. However, the
manufacturing or pretreatment process of them is compli-
cated, invasive, and time-consuming. It was thought that the
synthetic graft that had the potential to promote autologous tis-
sue regenerationwithout any seedingwould be more practicalThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 905
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bility of TEVGs in small-diameter artery reconstruction,
which were prepared by using a bioengineered material
made of collagen microsponge and a biodegradable polymer
scaffold. TEVGs used for carotid artery reconstruction in
a dog model had a 100% patency rate with no signs of throm-
bosis and showed good in situ tissue regeneration for up to 12
months without excessive neointimal hyperplasia or aneu-
rysm formation. These findings suggested that this graft had
sufficient durability and patency to be used for small-diameter
artery reconstruction.
In our previous study, we prepared a tissue-engineered
patch that could promote autologous tissue regeneration
without cell seeding and used it for vessel wall reconstruction
in large animal models.10 This tissue-engineered patch was
fabricated by compounding a collagen microsponge with
a biodegradable polymer scaffold composed of a PGA-knitted
mesh whose outside was reinforced with woven PLLA to
avoid rupture and aneurysm formation. In the present study,
we slightly changed the design of the polymer scaffold pre-
pared from the same materials to create a small-caliber tube
graft. We fabricated the core-sheath compound yarn using
Figure 6. The regenerated neointimal and medial wall thickness
of the proximal, middle, and distal portions of TEVGs 2, 4, 6, and
12 months after implantation. Error bars indicate standard devia-
tion. The wall thickness increased significantly over time from 2
to 6 months (*P < .05).
Figure 7. Biochemical analysis of collagen content in the neotis-
sue of TEVGs 2, 4, 6, and 12 months after implantation and that of
the native carotid artery (*P < .05).906 The Journal of Thoracic and Cardiovascular Surgery c OctPGA and PLLA fibers and constructed the small-diameter
tube graft in a plain weave pattern. The core-sheath yarn
composed of PLLA and PGA was fabricated by air-jet spin-
ning technology and had a porous 3-dimensional structure.
Cell culture in vitro showed that proliferation of the cells
seeded onto TEVGs with the collagen microsponge was sig-
nificantly higher than that onto TEVGs without the collagen
microsponge. This suggested that the porous 3-dimensional
structure and the collagen microsponge could provide a feasi-
ble microenvironment to facilitate the in vivo attachment and
expansion of autologous cells throughout TEVGs, even in
the absence of cell seeding.
Histologically, TEVGs had a 3-layered structure at all
points of time, which was reminiscent of the natural arterial
structure. The luminal surface of the newly formed tissue
(particularly the intima) showed complete endothelialization
with a confluent endothelial layer consisting of von Wille-
brand factor-positive cells. The endothelialization of TEVGs
was completed by at least 2 months after implantation. Endo-
thelial cells actively inhibit thrombosis and intimal hyperpla-
sia, and serve as an anticoagulant surface.13,14 Because of
complete endothelialization, TEVGs were free from throm-
bosis during the observation period, despite no antiplatelet
or anticoagulant drugs being used. In ePTFE grafts, the direct
exposure of ePTFE fibrils to the graft lumen and the irregu-
larity of the graft surface at defective sites might cause local
Figure 8. Biomechanical analysis showing tensile modulus and
tensile strength of TEVGs at preimplantation stage and 2, 4, 6,
and 12 months after implantation, and those of the native carotid
artery (*P < .05). MPa, Megapascal.ober 2008
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cidental thrombotic event. The central layer (essentially the
media) was composed of multilayered ECM alternating
with parallel-aligned a-smooth muscle actin positive smooth
muscle cells and residual scaffold materials. The outer sur-
face (essentially the adventitia) was composed of the loose
connective tissue. This process resembled a prototypical vas-
cular healing response but became progressively condensed
at longer intervals. The wound healing response to vascular
injury often evolves into a chronic condition of hyperprolif-
eration. Indeed, most studies on synthetic vascular prostheses
report massive intimal thickening and pathologically in-
creasedmatrix synthesis, which results in early graft occlusion
and failure.15 Therefore, we speculated that this process was
indicative of an in situ tissue remodeling process comparable
with healing. The results of neointimal and medial wall thick-
ness showed that in situ tissue regeneration in TEVGs by host
cells peaked 6 months after implantation and slowed down
subsequently. We thought that tissue regeneration stabilized
as soon as the process of graft remodeling was completed. In
this study, the precise mechanisms behind in situ regenera-
tion have not been evaluated. We can assume that the source
of intimal cells is not the anastomotic edges, because a graft
of 30 mm in length may prevent the migration of the cells
from the native aorta.12 We speculated that the source was
the fallout of circulating vascular progenitor cells followed
by their differentiation under flow conditions. Overall, it
seemed that TEVGs would be a more suitable microenviron-
ment for tissue regeneration by supplying an in situ bioreac-
tor and incubator for vascular progenitor cells without
formation of the hyperplastic tissue.
After complete regeneration of the neotissue, the collagen
content in its ECM layers was almost the same as that in the
native vascular tissue. Instead of collagen, significantly fewer
elastic fibers and a thinner elastic layer were observed in the
neotissue than in the native aorta; however, the elastic fibers
gradually became distinct. Biomechanical examination
showed that, after implantation, the strength of TEVGs and
neotissue decreased and that the pliability increased to almost
the same level of those of the native artery. We speculated
that ECM in the neotissue might withstand the aortic blood
pressure, although the strength of TEVGs reduced after graft-
ing because of hydrolysis and biological processes. More-
over, arterial pulsation and transmission of shear stress to
the graft wall might not be prevented, although the TEVG
scaffold remained intact.
The limitations of our study were the residual PLLA fibers
in the TEVG scaffold, and the graft size was considerably
large for clinical use. To withstand the aortic pressure,
PLLAwas used for preparing the graft scaffold. However, re-
sidual PLLA was noted until 12 months after implantation. It
was necessary to investigate whether the newly formed tissue
could withstand the aortic blood pressure even after complete
degradation of the graft scaffold; therefore, further long-termThe Journal of Thofollow-up was required. We needed to optimize the degrada-
tion time of the scaffold material, because the cellular struc-
tures and matrix were absorbed, until only the engineered
tissues remained without any foreign materials to withstand
the aortic pressure. For the next step, we should consider the
smaller and longer grafts for established use in grafting proce-
dures involving small-diameter vessels, such as the peripheral
arteries. Nevertheless, we believe that in situ tissue regenera-
tion using TEVGs that do not require pretreatment in the form
of cell seeding may be a useful strategy and may provide
further experimental justification for entering clinical trials.
Conclusions
Our study indicated that a novel tissue-engineered, small-
caliber, biodegradable vascular graft promoted in situ vascu-
lar tissue regeneration and did not require pretreatment in the
form of cell seeding, thereby conferring better patency on
small-diameter vascular grafts.
We acknowledge the excellent technical assistance of Shigeru
Matsunui and Tadashi Mukouyama.
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